DDInter704 DDInter629
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Everolimus {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Grepafloxacin
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) upregulates {v} (Gene) RSU1
RSU1 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Sarecycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Everolimus {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Everolimus (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) upregulates RSU1 (Gene) and RSU1 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Everolimus (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat